Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
about
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary diseaseStriving for optimal bronchodilation: focus on olodaterolDifferential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterolA rational approach to single, dual and triple therapy in COPDPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDPositioning new pharmacotherapies for COPDThe Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary DiseaseOnce-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by ageComparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.Olodaterol: a review of its use in chronic obstructive pulmonary disease.Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Updates in the management of stable chronic obstructive pulmonary disease.Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.Tiotropium/Olodaterol: A Review in COPD.Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.Systematic review comparing LABA, olodaterol, and indacaterol: limitations.Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease.Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
P2860
Q24186411-FD5C0332-6C46-42F1-B41D-06F8AD7CA7C8Q26752887-37B3CE92-91A8-4D20-B693-E9162BA1B14DQ26775244-0D250942-482F-4F33-8B02-0CDAFEE76BC1Q26776477-8BD204DF-DEC1-45BE-ABE0-6E51DBCA71FCQ26778685-31911523-B659-4EF9-BABD-6728DB1A45CAQ26798659-63A1724E-879C-46F6-94F6-6CCB89367D63Q28068078-73803F7D-1333-41A6-A535-9427E4488926Q34011640-4DADC12D-035C-4E48-B00C-F34F53C01DF5Q35538249-315BA1BC-FBD2-46F7-A277-6458E8067BBEQ35766346-FA664051-392A-4F8B-90DA-A5B446E24484Q35778149-0E0A3058-EA00-41E6-854A-F7A54EB3F061Q35875281-030B2524-D299-490C-AACD-E4C6DFD4B18FQ35965128-B0B41DDA-DFA1-497F-940D-EF1D0B5B9250Q35994264-16FC5466-222A-4A71-A155-9F0FAE5C2C23Q36158846-8BC2CCAA-C578-47F6-8662-1E1C1DB06BF6Q36729122-76FCDA67-0BDB-4AF7-BA74-890587A8A1C3Q37278903-154D3334-699F-490B-8285-CFD781D85B70Q37283438-360CB646-82CA-4A67-A19C-6F0A5C11624AQ37397852-0ED3CC26-B7E3-4F31-807A-01D7B0F0EDADQ37603579-640C71ED-E018-4AFC-8EC4-662E19CB52A8Q38379269-088FB3D5-8751-4748-8984-A52E0803190BQ38570714-C4AD308C-2D2F-477D-921D-CE9756940AF1Q38578596-3CB101D9-17CF-4E89-8F64-A316E2FF9A77Q38639661-71A3C785-FEA5-49B1-9658-1D5AC576EA1BQ38673383-14EF5534-F3EB-487E-B8D8-71CE4A13B1A4Q38690660-DE3590DB-0D25-4A29-8207-29B1BC6BBED3Q38982942-FDB6EB10-741C-4EBD-A259-76467B7DD330Q39037235-F9AEDF88-6366-4B6B-B2A5-C6180AE73A8DQ39627403-EC6ACC3C-8C5B-4EF7-B4E8-89AEFACB3A59Q39674585-65E043B9-9232-4469-BB32-80450C00BBD9Q42634011-D780AF5C-20B0-4993-A483-F2B9B020BC4AQ42645176-746D7B85-8F83-44C7-B987-73EEEF8D02C3Q47375559-7FF67B00-F611-4819-A9FB-7FC79586543AQ47657304-059CF1C8-8A96-429B-BD1E-90A6A297B9E6Q47915131-4C397EA8-3855-4C32-A99D-CA559AA6EE37Q47966525-E424C4E3-44BE-41E7-9420-84A52D70A44CQ55133367-516B3D87-4A16-4D8C-AC09-7E2417BEBA77
P2860
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Lung function efficacy and sym ...... two replicate 48-week studies.
@ast
Lung function efficacy and sym ...... two replicate 48-week studies.
@en
type
label
Lung function efficacy and sym ...... two replicate 48-week studies.
@ast
Lung function efficacy and sym ...... two replicate 48-week studies.
@en
prefLabel
Lung function efficacy and sym ...... two replicate 48-week studies.
@ast
Lung function efficacy and sym ...... two replicate 48-week studies.
@en
P2093
P2860
P921
P356
P1476
Lung function efficacy and sym ...... two replicate 48-week studies.
@en
P2093
Alan Hamilton
Andrea Koch
Lawrence Korducki
Lorna Hart
Maria Cristina De Salvo
Pierluigi Paggiaro
P2860
P304
P356
10.2147/COPD.S62502
P407
P577
2014-07-05T00:00:00Z